- Title: Subtitle
- The Efficacy of AR101, a Peanut-Derived Pharmaceutical for Oral Immunotherapy (OIT), Is Maintained and Tolerability Is Increased with Low-Dose Maintenance Therapy
- Creators
- J. Andrew Bird - Southwestern Medical CenterJonathan M. Spergel - Children's Hospital of PhiladelphiaStacie M. Jones - University of Arkansas for Medical SciencesRima A. Rachid - Boston Children's HospitalAmal H. Assa'ad - Cincinnati Children's Hospital Medical CenterJulie Wang - Icahn School of Medicine at Mount SinaiStephanie A. Leonard - Rady Children's Hospital-San DiegoSusan Stefanac Laubach - Rady Children's Hospital-San DiegoEdwin H. Kim - University of North Carolina at Chapel HillBenjamin P. Davis - Cincinnati Children's Hospital Medical CenterMichael J. Welch - Allergy and Asthma Medical Group and Research CenterJennifer Heimall - Children's Hospital of PhiladelphiaAntonella Cianferoni - Children's Hospital of PhiladelphiaAndrew J. MacGinnitie - Boston Children's HospitalElena Crestani - Boston Children's HospitalSean R. Bennett - Aimmune TherapeuticsBrian P. Vickery - University of North Carolina at Chapel HillRobert M. Elfont - Aimmune TherapeuticsA. Wesley Burks - University of North Carolina at Chapel Hill
- Resource Type
- Abstract
- Publication Details
- Journal of allergy and clinical immunology, Vol.137(2), pp.AB408-AB408
- Publisher
- Elsevier Inc
- DOI
- 10.1016/j.jaci.2015.12.1265
- ISSN
- 0091-6749
- eISSN
- 1097-6825
- Language
- English
- Date published
- 02/2016
- Academic Unit
- Stead Family Department of Pediatrics; Immunology; Internal Medicine
- Record Identifier
- 9984361574602771
Abstract
The Efficacy of AR101, a Peanut-Derived Pharmaceutical for Oral Immunotherapy (OIT), Is Maintained and Tolerability Is Increased with Low-Dose Maintenance Therapy
Journal of allergy and clinical immunology, Vol.137(2), pp.AB408-AB408
02/2016
DOI: 10.1016/j.jaci.2015.12.1265
Details
Metrics
8 Record Views